Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Intravacc
Deal Size : Undisclosed
Deal Type : Agreement
Intravacc and Celonic to Develop and Produce a Novel COVID-19 Vaccine
Details : Covid-19 vaccine is based on an immunogenic Spike (S) protein of SARS-CoV-2 combined with Intravacc's prorietary Outer Membrane Vesicle (OMV) technology".
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
July 29, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Intravacc
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Tel Aviv University
Deal Size : Undisclosed
Deal Type : Collaboration
TAU and Neovii Team Up to Develop Covid-19 Vaccine
Details : The deal provides Neovii with the exclusive right to develop and commercialise a platform technology created by Biotechnology professor Jonathan Gershoni of TAU’s School of Molecular Cell Biology, to rapidly identify epitope-based vaccines.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
May 13, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Tel Aviv University
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Tocilizumab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
China approves use of Roche arthritis drug for some Covid-19 patients
Details : Chinese researchers recently registered a three-month clinical trial for Actemra that would recruit 188 coronavirus patients and take place from Feb 10 to May 10.
Product Name : Actemra
Product Type : Antibody
Upfront Cash : Inapplicable
May 03, 2020
Lead Product(s) : Tocilizumab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Immunoglobulin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New COVID-19 Clinical Trial Supported by Octapharma USA
Details : The trial is entitled Randomized Open Label Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 16, 2020
Lead Product(s) : Immunoglobulin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
KD Pharma Group & SLA Pharma Initiate Clinical Trial For COVID-19
Details : EPAspire™ is shortly entering clinical trials as a promising candidate to treat patients with symptoms of the novel coronavirus infection. The MHRA in the UK has approved the trial.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 14, 2020
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable